A new technology has shown promise in treating several types of tumors in mice that do not respond to cancer immunotherapy medications called checkpoint inhibitors. Results from tests of the so-called Y-trap technology were reported in the article, “Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy,” that was